ERBB2 and breast carcinoma: Joint analyses of studies demonstrate that the complete pathological response after neoadjuvant treatment has evidence of improved survival free of oncological events related to breast cancer and overall survival, especially for triple negative tumors and isolated HER-2-positive [4,5,6].